Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Holding NKTR?
Track your performance easily
NKTR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.41 - $1.93
Previous Close$1.4
Volume2.39M
Average Volume (3M)1.16M
Market Cap
$244.83M
Enterprise Value$85.69M
Total Cash (Recent Filing)$271.24M
Total Debt (Recent Filing)$112.10M
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Nov 07, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding184,079,479
10 Day Avg. Volume1,937,658
30 Day Avg. Volume1,157,619
Standard Deviation0.19
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.23
Price to Sales (P/S)2.77
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.92
Enterprise Value/Gross Profit1.52
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$5.50Price Target Upside295.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Nektar Therapeutics News
Ownership Overview
10.83% Insiders
17.28% Mutual Funds
0.14% Other Institutional Investors
61.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $0.41 and its highest was $1.93 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Currently, no data Available
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is 3 days ago.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.185 by -$0.065.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -$0.2.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 184,079,480 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.185. Following the earnings report the stock price went down -8.264%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Among the largest hedge funds holding Nektar Therapeutics’s share is PRIMECAP Management Co. It holds Nektar Therapeutics’s shares valued at 7M.
---
Nektar Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (295.68% Upside)
$5.50 (295.68% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 295.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $27.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.0%
Last 30 Days ▲ 14.0%
Last 30 Days ▲ 14.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
154.54%
12-Months-Change
Fundamentals
Return on Equity
-128.02%
Trailing 12-Months
Asset Growth
-30.54%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
---
NKTR Earnings Call
Q2 2024
0:00 / 0:00
---
NKTR Stock 12 Month Forecast
Average Price Target
$5.50
▲(295.68% Upside)
Technical Analysis
Best Analysts Covering NKTR
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+49.01%
reiterated a sell rating 6 months ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +49.01% per trade.
---